CAS: 936446-61-6
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | NRC-2694 REF: IN-DA01EO8CCAS: 936446-61-6 | 99% | To inquire | Tue 07 Jan 25 |
 | NRC-2694 REF: TM-T16343CAS: 936446-61-6 | 99.38% | 82.00 €~1,034.00 € | Tue 14 Jan 25 |
 | NRC-2694 REF: 3D-LMB44661CAS: 936446-61-6 | Min. 95% | To inquire | Tue 18 Feb 25 |
Ref: IN-DA01EO8C
| 1mg | 150.00 € | ||
| 5mg | 309.00 € | ||
| 10mg | 599.00 € | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire | ||
| 200mg | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025
NRC-2694
CAS:936446-61-6
NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and …
Formula:
C24H26N4O3
Purity:
99.38%
Color and Shape:
Solid
Molecular weight:
418.49
Ref: TM-T16343
| 1mg | 82.00 € | ||
| 5mg | 155.00 € | ||
| 10mg | 241.00 € | ||
| 25mg | 409.00 € | ||
| 50mg | 542.00 € | ||
| 100mg | 780.00 € | ||
| 200mg | 1,034.00 € | ||
| 1mL*10mM (DMSO) | 170.00 € |
Estimated delivery in United States, on Tuesday 14 Jan 2025
NRC-2694
CAS:936446-61-6
NRC-2694 is a novel anilino-based oral solid formulation for the treatment of bladder cancer. NRC-2694 …
Formula:
C24H26N4O3
Purity:
Min. 95%
Molecular weight:
418.49 g/mol
Ref: 3D-LMB44661
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
